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Rsk1 mediates a MEK–MAP kinase cell survival signal
Akiko Shimamura*†‡, Bryan A. Ballif*‡, Stephanie A. Richards* and John Blenis*
Background: Growth factors activate an array of cell survival signaling pathways.
Mitogen-activated protein (MAP) kinases transduce signals emanating from their
upstream activators MAP kinase kinases (MEKs). The MEK–MAP kinase
signaling cassette is a key regulatory pathway promoting cell survival. The
downstream effectors of the mammalian MEK–MAP kinase cell survival signal
have not been previously described.
Results: We identify here a pro-survival role for the serine/threonine kinase
Rsk1, a downstream target of the MEK–MAP kinase signaling pathway. In cells
that are dependent on interleukin-3 (IL-3) for survival, pharmacological inhibition
of MEKs antagonized the IL-3 survival signal. In the absence of IL-3, a
kinase-dead Rsk1 mutant eliminated the survival effect afforded by activated
MEK. Conversely, a novel constitutively active Rsk1 allele restored the
MEK–MAP kinase survival signal. Experiments in vitro and in vivo demonstrated
that Rsk1 directly phosphorylated the pro-apoptotic protein Bad at the serine
residues that, when phosphorylated, abrogate Bad’s pro-apoptotic function.
Constitutively active Rsk1 caused constitutive Bad phosphorylation and
protection from Bad-modulated cell death. Kinase-inactive Rsk1 mutants
antagonize Bad phosphorylation. Bad mutations that prevented phosphorylation
by Rsk1 also inhibited Rsk1-mediated cell survival. 
Conclusions: These data support a model in which Rsk1 transduces the
mammalian MEK–MAP kinase signal in part by phosphorylating Bad.
Background
Cell survival and proliferation require timely signals from
extracellular growth factors for normal tissue develop-
ment and maintenance. The molecular mechanisms
underlying the remarkable efficiency with which growth
factors inhibit the cellular apoptotic machinery have
come under intensive investigation. The strength of any
one growth factor’s pro-survival effect is derived from the
additive effects of the multiple downstream survival sig-
naling pathways it activates [1,2]. Multiple survival ago-
nists acting in concert target an even broader spectrum of
survival pathways, providing synergistic survival sig-
nalling [3]. The multiplicity of survival signals and the
gradation of their strength offer an organism exquisite
regulatory control over the development and mainte-
nance of cells for any given tissue. Molecular dissection of
individual survival pathways emanating from a given
growth factor is essential to elucidate the processes
leading to both normal tissue activity as well as diseases
characterized by inappropriate cell survival or excessive
cell death.
The signal transduced by mitogen-activated protein
(MAP) kinases and their upstream activators MAP kinase
kinases (MEKs) is a key pathway promoting cell survival
in response to growth factors [2,4–6]. Whereas the
Drosophila pro-apoptotic protein Hid, which so far lacks
known mammalian homologues, is a molecular target of
the MAP kinase survival pathway during fly develop-
ment [7,8], the mammalian downstream effectors of the
MEK–MAP kinase cell survival signal have not been
identified to date.
Mek1 and Mek2 activate the MAP kinases Erk1 and
Erk2, which in turn play a critical role in the activation of
the 90 kDa ribosomal S6 kinases (RSKs), serine/threo-
nine kinases that are activated in response to mitogenic
stimuli [9–12]. RSK activation is complex and requires
phosphorylation at several sites, the regulation of which is
only partially understood [10,13]. Members of the RSK
protein kinase family contain two kinase domains. The
carboxy-terminal kinase domain has not been shown to
have phosphotransferase activity toward any exogenous
substrates to date, and appears to be important for
autophosphorylation and activation of the amino-terminal
kinase domain. The latter is responsible for the phospho-
rylation of all known RSK substrates, which include the
transcription factor c-Fos [14], the cAMP response
element binding protein (CREB) [15], the transcriptional
inhibitor IκB [16], the estrogen receptor [17] and the
kinase Myt 1 [18]. As several RSK substrates have been
implicated in the regulation of cell survival, we hypothe-
sized that the MEK–MAP kinase survival signal could be
transduced by RSKs.
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Results
Interleukin-3 (IL-3) is a potent agonist of a number of sig-
naling cascades in hematopoietic cells, including signals
emanating from the phosphoinositide (PI) 3-kinase–
protein kinase B/Akt pathway, the MAP kinase pathway
and the protein kinase A (PKA) pathway [19–21]. The
murine hematopoietic cell line 32D is dependent on
IL-3 for survival [22]. The contribution of the
MEK–MAP kinase pathway to IL-3-dependent survival
was evaluated using chemical inhibitors of Mek1/2. In
the continued presence of IL-3, either of the two
MEK1/2-specific inhibitors PD098059 and U0126
induced apoptosis up to threefold compared to control
vehicle-treated cells  (Figure 1a). The diminished ability
of IL-3 to suppress apoptosis in the absence of MEKs
was consistent with other studies demonstrating a MEK-
dependent survival signal in these cells [19]. As pre-
dicted from the multiplicity of survival pathways
activated by IL-3, the effect of removing all IL-3-medi-
ated survival signals was greater than the effect of
inhibiting the MEK pathway alone and resulted in
80–90% apoptosis in this assay (data not shown). Intro-
duction of constitutively active Mek1 (Mek-DD) into
these cells promoted cell survival in the absence of IL-3
(Figure 1c). As expected from the pharmacological data
in Figure 1a, Mek-DD alone was insufficient to restore
the entire survival effect of IL-3 that is observed when
all downstream survival pathways are activated in
concert. Nonetheless, Figure 1a indicates that the
remaining survival signals were not sufficient to com-
pensate completely for the absence of the MEK signal. 
To test the hypothesis that the MEK survival signal was
transduced by Rsk1, the ability of a kinase-inactive Rsk1
mutant to block MEK-mediated cell survival was assayed.
As shown in Figure 1c, cotransfection of Mek-DD
together with a kinase inactive Rsk1 allele (Rsk1∆∆),
which carries inactivating point mutations in both the
amino-terminal and carboxy-terminal kinase domains
(K112R,K464R), eliminated the protective effect of
Mek-DD. As a control, co-expression of wild-type Rsk1
did not affect Mek-DD-mediated protection.
To further test this hypothesis, a novel constitutively active
Rsk1 mutant was constructed. To date, RSKs have proven
refractory to a point-mutant approach towards generating a
constitutively active allele ([11] and data not shown). As the
catalytic loop in Rsk1’s amino-terminal kinase domain is
phosphorylated and activated by PDK1 [23,24], a myristoy-
lation sequence was added to the amino terminus of avian
Rsk1. Whereas wild-type Rsk1 was inactive in the
absence of serum, myristoylated Rsk1 maintained kinase
activity following serum withdrawal (Figure 1b). Western
blots confirmed that under these serum-starvation condi-
tions, Erk proteins were inactive, as shown by the
absence of the slower migrating phosphorylated polypep-
tides (Figure 1b). Consistent with its high degree of
homology with avian Rsk1, human Rsk1 also exhibited
constitutive activity following myristoylation (data not
shown). When introduced into 32D cells, myristoylated
avian Rsk1 protected cells from IL-3 withdrawal to an
extent comparable to that observed with activated
Mek-DD (Figure 1c). The inhibition of the MEK survival
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Figure 1
Rsk1 mediates Mek1/2-dependent cell
survival in 32D cells. (a) Inhibition of
endogenous Mek1/2 promotes apoptosis in
32D cells in the presence of IL-3. Cells were
treated with dimethyl sulfoxide (DMSO;
vehicle), PD098059 or U0126 in the
presence of IL-3 as described in the Materials
and methods. The number of viable cells was
scored by trypan blue staining after 24–30 h
of treatment and converted to the percentage
of cells that were nonviable. Error bars
represent the SEM of three separate
experiments. (b) Myristoylated avian Rsk1
(Myr–Rsk1) remains active in the absence of
serum. Serum-starved HEK 293E cells
transfected with either wild-type or
myristoylated avian Rsk1 were stimulated for
10 min with serum as indicated. Whole cell
lysates were analyzed by immunoblotting with
an avian-specific anti-Rsk1 antibody
(anti-Rsk1(Av)) and anti-Erk1/2 antibodies as
indicated. Whole cell lysates were also
immunoprecipitated with the anti-Rsk1(Av)
antibody and immune-complex kinase assays
were performed using GST–S6 as a
substrate. Kinase activity was measured by
the intensity of radioactive labeling of the
substrate band on a polyacrylamide gel (data
not shown) and quantitated using
phosphorimaging (graph). (c) Myristoylated
Rsk1 and activated Mek1 (Mek1-DD) promote
IL-3-independent survival, whereas
kinase-dead Rsk1 eliminates Mek1-DD
protection. Cells were transfected with the
indicated constructs, as described in the
Materials and methods; WT, wild type.
At 5–7 h post-transfection, the cells were
starved of IL-3 for 14–18 h. GFP-positive cells
were scored for apoptosis, as measured by PI
uptake. The maximum level of apoptosis
measured was around 60%. Results are
expressed as percentage protection relative
to that given by the vector for each
independent experiment. Error bars represent
the SEM for three independent experiments.
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signal by kinase-inactive Rsk1, together with the restora-
tion of the survival signal with activated Rsk1 supports a
role for Rsk1 in transducing the MEK survival signal.
How might Rsk1 promote cell survival? As growth-factor-
mediated survival has been shown to correlate with phos-
phorylation of the pro-apoptotic Bcl-2-related protein Bad
in 32D cells in a manner dependent on MEKs [19], and as
a growing number of reports implicate the MEK–MAP
kinase pathway in phosphorylation of Bad [19,25,26], we
explored the potential relationship between Rsk1 and
Bad. To test whether Bad is phosphorylated by Rsk1
in vitro, HEK 293E cell lysates were immunoprecipitated
using antibodies against endogenous Rsk and immune-
complex kinase assays were performed using the bacteri-
ally expressed glutathione-S-transferase (GST)-conjugated
substrate GST–Bad or, as a positive control, GST–S6. As
an additional positive control, immune-complex kinase
assays were performed from these same lysates using anti-
bodies against Akt with GST–Bad and GST–glycogen
synthase kinase (GSK)-3β as substrates. Following serum
stimulation, immunoprecipitated RSKs directly phospho-
rylated both GST–S6 and GST–Bad (Figure 2a). Under
these conditions in HEK 293E cells, Akt was poorly acti-
vated by serum but responded well to insulin. Conversely,
Rsk was poorly activated by insulin. Transfected kinase-
inactive Rsk1 demonstrated no detectable kinase activity
toward recombinant GST–Bad (Figure 2b). Given these
data, it is likely that Rsk1 phosphorylates Bad directly
rather than via an additional coprecipitating kinase.
To determine which residues were phosphorylated by Rsk
in vitro, recombinant GST–Bad point mutants carrying
serine-to-alanine mutations at positions Ser112 (S112A) or
Ser136 (S136A) or both (S112A,S136A) were used as kinase
assay substrates for endogenous RSKs (Figure 2c,d). Con-
sistent with studies demonstrating Akt’s specificity for the
Ser136 residue [27], Akt showed little kinase activity
towards Bad mutants carrying the S136A mutation. Muta-
tion of the Ser112 residue partially decreased Bad phos-
phorylation by Rsk. Although the phosphorylation of the
S136A mutant was comparable to that of wild-type Bad
under these conditions of substrate excess, mutation of
both Ser112 and Ser136 further reduced Rsk phosphoryla-
tion of Bad below that seen with the S112A mutation
alone. These in vitro data indicate that endogenous Rsk is
capable of phosphorylating Bad at both Ser112 and Ser136,
with a preference for the Ser112 site. Consistent with Rsk’s
phosphorylation of Bad in vitro, 32D cells treated with the
Mek1/2 chemical inhibitors PD098059 or U0126 showed
corresponding reductions in endogenous MAP kinase acti-
vation, endogenous phosphorylation of Bad at Ser112 and
endogenous Rsk kinase activity (Figure 2e).
To determine whether myristoylated Rsk1 conferred cons-
titutive phosphorylation of Bad in the absence of serum
in vivo, HEK 293E cells were transfected with GST–Bad
together with either wild-type or myristoylated Rsk1. Fol-
lowing 24 hours of serum deprivation, cells were lysed
before or after 10 minutes of serum stimulation. Expression
levels of the transfected Rsk1 and GST–Bad constructs are
shown in Figure 3a. Cotransfection of myristoylated Rsk1
reduced the mobility of the GST–Bad protein in both the
presence and the absence of serum. To aid normalization of
Bad expression levels, the lysates were run on a higher per-
centage gel, causing all forms to run at the same position.
The blot was then stripped and reprobed with antibodies
specific to Bad phosphorylated on Ser112 or Ser136 (anti-
Bad pS112 and anti-Bad pS136). Transfection with myris-
toylated Rsk1 resulted in constitutive phosphorylation of
Bad at both Ser112 and Ser136 (Figure 3a).
Kinase-inactive Rsk1 mutants were tested for their ability
to block Bad phosphorylation in vivo. As shown in
Figure 3b, a plasmid encoding GST–Bad was cotransfected
with the kinase-inactive Rsk1 mutant (Rsk1∆∆). Cells were
serum-starved and then stimulated and lysates were ana-
lyzed by western blotting. Following serum stimulation, the
anti-Bad pS112 antibody signal was reduced in cells
cotransfected with Rsk1∆∆. A similar result was obtained
using a Rsk1 construct with a single point mutation in the
amino-terminal kinase domain (Rsk1 K112R; data not
shown). Probing with anti-Bad pS136 showed little effect of
the kinase-inactive Rsk1 at that site (Figure 3b, lanes 5 and
6), consistent with the observation that alternative kinases
such as Akt can also phosphorylate this site. An anti-GST
western blot confirmed that these differences could not be
attributed to differences in Bad expression levels.
To test whether crosstalk between the Akt and Rsk1 path-
ways could lead to Bad phosphorylation, myristoylated
Rsk1 was tested for its ability to activate wild-type Akt and
myristoylated Akt was tested for its ability to activate wild-
type Rsk1. Figure 4 shows that, in the absence of serum, no
wild-type Akt kinase activity was observed with or without
cotransfected myristoylated Rsk1 (compare lanes 7 and 13).
Wild-type Akt is poorly activated by serum in HEK 293E
cells; in control experiments, however, this wild-type Akt
construct showed strong Akt kinase activity in response to
stimuli such as insulin (data not shown). Conversely, no
wild-type Rsk1 kinase activity was observed in the pres-
ence of myristoylated Akt (compare lanes 9 and 11). Thus,
Rsk1 phosphorylates Bad independently of Akt. Rsk1 phos-
phorylation of Bad is also independent of PKA, as the
phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA),
which stimulates the MAP kinase pathway and Rsk1 but
not PKA in HEK 293E cells, also leads to Bad phosphoryla-
tion at Ser112, a result prevented by the Mek1/2 inhibitor
PD098059 (data not shown).
To investigate the connection between the effect of Rsk1
on survival and its phosphorylation of Bad, we turned to
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Figure 2
Rsk phosphorylates Bad in vitro. (a) Endogenous Akt or Rsk was
immunoprecipitated (IP) from lysates of HEK 293E cells starved in
serum-free media for 24 h prior to stimulation with 0.1 µM insulin
(ins; 20 min) or 10% serum (10 min). Kinase assays using bacterially
expressed GST–Bad, GST–S6 or GST–GSK3β as substrates were
performed as described in the Materials and methods. Kinase activity
was measured by the intensity of radioactive labeling of the substrate
band on a polyacrylamide gel (top) and quantitated using
phosphorimaging (bottom). Only the results with GST–Bad are
quantitated. (b) Hemagglutinin-labeled kinase-inactive Rsk1
(HA–Rsk1∆∆) shows no associated kinase activity toward Bad.
Lysates from serum-stimulated HEK 293E cells transfected with the
indicated Rsk1 constructs were analyzed by immunoblotting with an
anti-HA antibody. Anti-HA immune-complex kinase assays using
GST–Bad as a substrate were performed. (c,d) Endogenous Rsk
phosphorylates Bad at Ser112 and Ser136 in vitro. Serum-starved
HEK 293E cells were stimulated as in (a) and immune-complex kinase
assays were performed using (c) anti-Akt or (d) anti-Rsk antibodies
and GST–Bad mutant substrates as indicated. (e) Inhibition of
endogenous Mek1/2 and Rsk blocks endogenous phosphorylation of
Bad at Ser112 in 32D cells. Cells were starved of IL-3 for 3.5 h.
DMSO, PD098059 (50 µM) or U0126 (5 µM) were added as
indicated for 30 min prior to the re-addition of recombinant IL-3 for
10 min. Bad was immunoprecipitated and detected by western blot
using the indicated antibodies. Densitometry analysis (data not shown)
revealed a 3.6-fold decrease in the anti-BAD pS112 antibody signal
with PD98059 and a 17-fold decrease with U0126 relative to the
DMSO control. Anti-Erk1/2 immunoblots and anti-Rsk
immune-complex kinase assays show that Mek1/2 inhibitors reduce
the IL-3-induced kinase activity of Erk1/2 and Rsk, respectively.
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the FL5.12 cell system developed by Stan Korsmeyer and
colleagues [28]. We used FL5.12 cells that stably express
both Bad and the related anti-apoptotic protein Bcl-xL
(FL5.12–Bcl-xL–Bad cells), which have been shown to
undergo apoptosis following IL-3 withdrawal in a manner
dependent on the phosphorylation state of Bad. The
phosphorylation of the Bad Ser112 and Ser136 sites in
these cells antagonizes Bad’s binding to and disabling of
Bcl-xL [28]. IL-3 activated both endogenous MAP kinase
and endogenous Rsk in FL5.12–Bcl-xL–Bad cells
(Figure 5a). Constitutively active Rsk1 conferred constitu-
tive phosphorylation of Bad at Ser112 (Figure 5b) and, as
in 32D cells, partially restored protection from apoptosis
following IL-3 withdrawal (Figure 5c). To test whether
part of Rsk1’s survival effect occurred through Bad phos-
phorylation, the survival effect of constitutively active
Rsk1 was assayed in FL5.12 cells stably expressing a
Bad construct containing serine-to-alanine substitutions
at both Ser112 and Ser136. Western blot analysis con-
firmed that equivalent levels of Bad were expressed in
each cell line ([28] and data not shown). Two-thirds of
Rsk1’s protective effect was abrogated by co-expression
of this mutant form of Bad (Figure 5c). To control for
potential cell-line-dependent variations, the survival in
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Figure 3
Rsk1 phosphorylates Bad in vivo. (a) Myr–Rsk1 induces
growth-factor-independent Bad phosphorylation. HEK 293E cells
transfected with GST–Bad together with either wild-type Rsk1 or
Myr–Rsk1 were serum-starved then stimulated with serum for 10 min
as indicated. Lysates were analyzed by immunoblotting with the
indicated antibodies; anti-Rsk1(Av), avian-specific anti-Rsk1 antibody.
Electrophoresis was performed on 10% polyacrylamide gels in the top
two panels to visualize polypeptide mobility shifts and on 12% gels in
the bottom three panels to facilitate quantitation. Densitometric
analysis (data not shown), normalized for GST–Bad expression,
showed that Myr–Rsk1 induced similar increases in phosphorylation of
Bad at Ser112 or Ser136 in the presence or the absence of serum.
(b) Kinase-inactive Rsk1 antagonizes Bad phosphorylation. HEK 293E
cells transfected with GST–Bad and K112R/K464R Rsk1 (Rsk1∆∆)
as indicated were serum-starved and stimulated as in (a). Lysates were
analyzed by immunoblotting with the indicated antibodies. 12%
polyacrylamide gels, which abrogated polypeptide mobility shifting,
were run in the bottom three panels to facilitate quantitation.
Densitometric analysis (data not shown) showed that kinase-inactive
Rsk1 induced a 40% decrease in signal with the anti-Bad pS112
antibody (lane 6), but no decrease in signal was detected with the
anti-Bad pS136 antibody (lane 6) relative to controls (lane 5).
Figure 4
Rsk1 and Akt phosphorylate Bad independently. HEK 293E cells
transfected with the indicated constructs were serum-starved and then
stimulated with serum as indicated. Immune-complex kinase assays using
either avian-specific anti-Rsk1 (anti-Rsk1(Av)) or anti-HA antibodies and
the substrate GST–Bad were performed. Protein expression was
determined by immunoblotting with the indicated antibodies.
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the presence of myristoylated Rsk1 was reported relative
to that with vector controls for each cell line. The residual
Rsk1 survival effect observed with the double Bad mutant
raises the exciting possibility that Rsk1, like Akt, may
target multiple survival pathways. 
Discussion
The molecular mechanisms underlying the mammalian
MEK–MAP kinase survival pathway have not been previ-
ously described. This study supports a novel role for Rsk1
as a downstream effector of the MEK–MAP kinase sur-
vival signal. Kinase-inactive Rsk1 blocked the MEK sur-
vival signal and constitutively active Rsk1 restored the
survival effect observed with activated Mek1. Further-
more, these studies identified Bad as one target through
which Rsk1 could promote cell survival.
The emerging complexity and interplay between multiple
survival signaling pathways has been the focus of two
recent reviews [1,2]. It is intriguing to note that upstream
regulators of Rsk1, such as the small GTPase Ras, can
activate multiple survival pathways. The MEK pathway is
one component of the Ras survival pathway, and Ras point
mutations that prevent Ras-dependent activation of
MEKs partially inhibit the Ras survival effect [29]. Our
data support the observation that these additional survival
signals are insufficient to fully compensate for the loss of
the MEK signal in certain cell types. The magnitude of
Ras-mediated cell survival represents the additive effects
of multiple downstream survival mechanisms of which the
MEK–MAP-kinase–Rsk1 pathway is one. It is likely that
the interplay between multiple signals influences the final
outcome with regard to cell survival and that the
MEK–Rsk1 survival signal to Bad and other substrates
acts within this context. 
An important link between kinase signaling pathways and
the cellular apoptotic machinery was made following the
discovery that Bad undergoes phosphorylation at the
Ser112 and Ser136 positions in response to IL-3 or
insulin-like growth factor 1 (IGF-1) [21,27,28,30]. Bad
promotes apoptosis at least in part by dimerizing with and
inactivating Bcl-xL [28]. Phosphorylation of Bad at either
Ser112 or Ser136 abrogates its pro-apoptotic function by
promoting its dissociation from Bcl-xL [28]. Once phos-
phorylated at either or both sites, Bad binds to 14-3-3 pro-
teins in an interaction that has been proposed to
sequester Bad from Bcl-xL [28]. A strikingly extensive
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Figure 5
Rsk1 phosphorylates Bad and protects FL5.12–Bcl-xL–Bad cells from
the apoptosis induced by IL-3 withdrawal. (a) IL-3 activates Rsk in
FL5.12–Bcl-xL–Bad cells. Cells were deprived of IL-3 for 4 h prior to
10 min of IL-3 stimulation (0.5 ng/ml). Cell lysates were analyzed by
immunoblotting with the antibodies indicated. Immune-complex kinase
assays of endogenous Rsk were performed using a GST–Bad
substrate. (b) Myr–Rsk1 promotes Bad phosphorylation in
FL5.12–Bcl-xL–Bad cells. Cells transfected with either empty vector
(lane 2) or Myr–Rsk1 (lane 3) were lysed 4 h post-transfection and
whole cell lysates were analyzed by immunoblotting with the indicated
antibodies; anti-Rsk1(Av), avian-specific anti-Rsk1 antibody. Lane 1
shows an untransfected FL5.12-Bcl-xL parental cell line as a control.
By densitometric analysis, Myr–Rsk1 induced a sixfold increase in the
anti-Bad pS112 antibody signal (lane 3) relative to vector (lane 2).
Anti-Rsk1(Av) immune-complex kinase assays using GST–Bad as
substrate are shown in the bottom panel. (c) Bad S112A,S136A
double mutants antagonize the Rsk1 survival signal.
FL5.12–Bcl-xL–Bad cells containing either the wild-type (WT) or the
S112A,S136A version of Bad were electroporated with GFP and
Myr–Rsk1. Apoptosis was assayed as described in the Materials and
methods; the maximal level of apoptosis was between 46% and 56%.
Percentage protection against apoptosis is measured relative to vector
control for each cell line for each independent experiment. Error bars
represent the SEM for three independent experiments.
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array of separate signaling pathways regulates Bad’s apop-
totic activity. Akt phosphorylates Bad at Ser136 upon
IGF-1 or IL-3 stimulation [21,27]. PKA can phosphory-
late Bad at Ser112 [20] and calcineurin can promote apop-
tosis by dephosphorylating and hence activating Bad [31].
Mek1/2-dependent Bad phosphorylation has also been
described in some cell systems [19,25,26], and our data
now identify Rsk1 as a MEK-dependent Bad kinase. 
Although Bad’s antagonism of Bcl-xL activity plays an
important role in apoptosis in some cell systems, Bad is
not universally required for apoptosis to occur [25,32].
One reason for this could be the composite variability of
expression and regulation of pro- and anti-apoptotic
members of the Bcl-2 family. Bad expression levels are
variable between different tissues [33] and the ratios
between the pro- and anti-apoptotic members of the Bcl-2
family have been proposed to function as a rheostat, with
the combined expression levels and functional state of all
family members finally tipping the scales of cell fate
toward either life or death [34]. 
Conclusions 
This study has identified Rsk1 to be a critical mediator of
the MEK–MAP kinase cell survival signal and identifies
Bad as one target of the Rsk1 survival pathway. Like the
kinases Akt and PKA, Rsk1 probably promotes cell sur-
vival via targets in addition to Bad (Figure 6). The Akt cell
survival signal is mediated by several mechanisms in addi-
tion to Bad phosphorylation, such as phosphorylation of
Caspase-9 [35], CREB [36], GSK-3β [37], the Forkhead
transcription factor FKHRL1 [38], and IκΒ kinase [39,40].
Likewise, PKA has also been shown to phosphorylate both
Bad [20] and CREB [41]. As we observed a residual Rsk1
survival effect in FL5.12 cells expressing a form of Bad
that could no longer be phosphorylated at Ser112 and
Ser136, it is likely that Rsk1 substrates in addition to Bad
play a role in apoptosis. It is intriguing that Rsk1 also
phosphorylates a number of substrates associated with
apoptosis, such as IκB [16] and the transcription factors
CREB [15] and c-Fos [14]. Thus, in addition to regulating
cell survival via post-translational mechanisms, Rsk1, like
Akt, probably contributes to transcriptionally governed
survival pathways. Further investigation into the novel
pro-survival function of Rsk1 is needed to elucidate the
roles of additional Rsk1 substrates in MEK–MAP kinase-
mediated cell survival.
Materials and methods
Cell culture, transfection and electroporation
E1A-transformed human embryonic kidney 293 (HEK 293E) cells
were maintained in DMEM supplemented with 10% heat-inactivated
fetal bovine serum (FBS). Transfection was by calcium phosphate pre-
cipitation; the total amount of DNA per transfected 60 mm dish was
3–5 µg. FL5.12 cells stably expressing Bcl-xL together with either
wild-type or mutant Bad (FL5.12–Bcl-xL–Bad cells; a gift of S.
Korsmeyer) were cultured as described [28] except that recombinant
IL-3 (0.5 ng ml–1) was used instead of WEHI-cell-conditioned media.
The 32D cells (a gift of M. Meyers) were maintained in RPMI medium
supplemented with 10% FBS and 5% WEHI-conditioned medium as
a source of IL-3. For electroporation, the cells were pelleted and
resuspended in 10% FBS in RPMI1640 without phenol red (Gibco
BRL) at a concentration of 1–1.5 × 107 cells per 500 µl. A 500 µl
aliquot of this cell suspension was added to a total of 20 µg DNA for
each electroporation. The Rsk1 mutant plasmids were transfected at a
9:1 ratio (µg:µg) relative to the GFP plasmid to ensure that GFP-posi-
tive cells would also carry the gene of interest. Electroporation set-
tings were 300 V and 800 µF for FL5.12 cells and 250 V and 800 µF
for 32D cells. Electroporation was performed using a BioRad electro-
poration unit and 0.4 cm cuvettes. Cells were permitted to recover for
5–10 min and then gently transferred to 15–25 ml of antibiotic-free
culture media for 5–10 h prior to apoptosis assays and biochemical
analysis. Transfection efficiencies ranged between 25–40% for
FL5.12 cells and 10–20% for 32D cells.
Immunoprecipitation, in vitro kinase assays, immunoblotting
and antibodies
For HEK 293E cells, cells were washed once with serum-free DMEM
and then returned to the same medium for 24 h prior to stimulation with
either 10% FBS for 10 min or insulin (0.1 µM) for 20 min as indicated
in the figure legends. For FL5.12 and 32D cells, the cells were washed
three times in 10–15 ml volumes of serum-free, IL-3-free Iscove’s modi-
fied Dulbecco’s medium (IMEM) or RPMI and then incubated in the
same for 2–4 h prior to stimulation with recombinant IL-3 (0.5 ng ml–1)
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Figure 6
Model in which the Bad kinases Akt, PKA and Rsk1 mediate cell
survival by phosphorylating an array of effector molecules. Survival
factors trigger diverse signaling pathways, which activate kinases that
can neutralize the pro-apoptotic effects of Bad. These three known
kinases, the cAMP-dependent kinase PKA, the PI 3-kinase-dependent
kinase Akt and now the MEK–MAP kinase-dependent kinase Rsk1, not
only regulate the phosphorylation state of Bad but also of a variety of
effector molecules implicated in apoptotic regulation. This offers the
cell a sensitive combinatorial means by which it can regulate the
triggering of the apoptotic program. P, phosphorylation.
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for 10 min. Prior to lysis, cells were washed once in ice-cold PBS and
then lysed in lysis buffer (pH 7.2) composed of 0.5% NP40 (or
IPEGAL), 0.1% Brij-35, 0.1% sodium deoxycholate (NaDOC), 1 mM
EDTA, 7 mM K2HPO4, 3 mM KH2PO4, 5 mM EGTA, 10 mM MgCl2,
50 mM β-glycerolphosphate, 1 mM Na vanadate, 2 mM DTT, 5 µg ml–1
pepstatin A, 10 µg ml–1 leupeptin and 1 mM phenylmethylsulfonyl fluo-
ride (PMSF). Lysates were then cleared by spinning for 10 min at 4°C
and 14,000 rpm in an Eppendorf microcentrifuge. Immunoprecipitation
kinase assays were performed on lysates containing 250–500 µg
protein. Lysates were incubated with the indicated antibodies for
1–3 h, then incubated for an additional hour with 20–30 µl of a 50%
slurry of Protein-A–Sepharose beads (Sigma) in PBS. The beads were
washed once with Buffer A composed of 1% NP40, 0.5% NaDOC,
100 mM NaCl, 10 mM Tris pH 7.2, 1 mM EDTA, 1 mM Na vanadate,
2 mM DTT and 1 mM PMSF; once with Buffer B composed of 1M
NaCl, 0.1% NP40 (or IPEGAL), 10 mM Tris pH 7.2, 1 mM Na vana-
date, 2 mM DTT and 1 mM PMSF; once with ST buffer composed of
150 mM NaCl, 10 mM Tris pH 7.2 and 1 mM PMSF; and once with
20 mM HEPES, 10 mM MgCl2. The kinase assays were performed by
adding 30 µl of kinase buffer composed of 20 mM HEPES pH 7.2,
10 mM MgCl2, 100 µg ml–1 BSA, 3 mM β-mercaptoethanol, 50 µM
ATP, 10 µCi [γ32P]ATP and 2–3 µg of recombinant substrate. Reac-
tions were incubated for 30 min at 30°C and were stopped by adding
10 µl of 4× sample buffer and boiling for 3 min. Reactions were sub-
jected to SDS–PAGE on 12% gels and quantitation was accom-
plished by phosphorimaging. For immunoblots, 20–100 µg of protein
lysate per lane were analyzed by SDS–PAGE on 10% gels, except as
otherwise indicated in the figure legends, and as noted below for
endogenous Bad. The proteins were transferred to nitrocellulose mem-
branes, blocked in 5% milk in PBST (PBS + 0.2% Tween-20), probed
with the indicated antibodies and visualized using enhanced chemilumi-
nescence (NEN). For detection of endogenous Bad in 32D cells,
5 × 108 cells were lysed in 750 µl of lysis buffer, immunoprecipitated
with 5 µl of anti-Bad antibody (Santa Cruz), washed three times in lysis
buffer, boiled in sample buffer and subjected to SDS–PAGE on a 10%
gel. Protein was then transferred to a nitrocellulose membrane and
blocked in 5% milk in Tris-buffered saline containing 0.2% Tween-20.
Anti-Bad antibody (R&D Systems) was used as primary probe and
Protein-A–horseradish peroxidase (HRP) was used as secondary
probe. Visualization was accomplished using enhanced chemilumines-
cence (NEN). Densitometry measurements were performed using a
Biorad imaging system and Quantity One software. Commercial anti-
bodies were obtained and used as directed from the following sources:
anti-Akt, UBI; anti-Bad, R&D Systems, Santa Cruz; anti-Bad pS112,
NEB; anti-Bad pS136, NEB; Protein-A–HRP secondary probe, Pierce.
The rabbit polyclonal anti-GST antibody was a gift from T. Rapaport.
Rabbit polyclonal anti-Rsk, avian-specific anti-Rsk1 and anti-Erk1/2
antibodies were made as described [10]. Results presented are repre-
sentative of three independent experiments.
Apoptosis assays
To induce apoptosis, FL5.12 (or 32D) cells were washed three times in
10–15 ml volumes of IMEM (Gibco BRL; or RPMI for 32D cells).
Electroporated cells were then subjected to centrifugation through 3 ml
Ficoll cushion for 30 min at 2,000 rpm and viable cells at the interface
were collected. Viable cells were then incubated in IMEM containing
10% FBS (or RPMI containing10% FBS for 32D cells) without IL-3 (or
without WEHI medium for 32D cells) for 13–18 h. Cells were then incu-
bated with PI (40 mg ml–1) to identify nonviable cells and analyzed by flu-
orescence-activated cell sorting, gating on GFP-positive transfected
cells. Markedly diminished GFP-positivity was noted by 48–72 h post-
transfection. Percentage protection relative to vector controls was calcu-
lated as 100 × [1–(% apoptosis of cells transfected with test
plasmid(s)/% apoptosis of cells transfected with vector plasmid)]. For
drug-induced apoptosis and inhibition of Bad phosphorylation, 32D cells
were starved of IL-3 for 3.5 h. DMSO, PD098059 (50 mM in DMSO,
Calbiochem) or U0126 (5 mM in DMSO, RBI) were added as indicated
for 30 min prior to the re-addition of recombinant IL-3 (0.01 ng ml–1).
After 10 min, lysates were made for immunoanalysis or, for cell death
analysis, viable cells were scored by trypan blue after 24–30 h of treat-
ment. Rsk1 activation following IL-3 starvation was greatly inhibited by
prior drug treatment whereas activated Rsk1 was not turned off by the
subsequent addition of the drug (data not shown). Correspondingly, the
pro-apoptotic effect of these drugs required a short period of IL-3 starva-
tion to quiesce Rsk1 prior to drug treatment and IL-3 addition. This
argues against a non-specific toxicity of the drugs. Importantly, the
vehicle control demonstrated little apoptosis, so the initial short starva-
tion was insufficient to account for the increased apoptosis.
Plasmids and constructs
All transfected Rsk1 constructs used in these studies were derived from
the avian Rsk1 cDNA, and were detected using avian-specific Rsk1
antibodies. Avian Rsk1 shares greater than 80% identity with murine,
human and Xenopus Rsk1 and they are regulated in a similar fashion
[12,13,42,43]. GST–GSK3β was generated by placing Met1–Ala22 of
human GSK3β (a gift of B. Neel) into pGEX-3X (Pharmacia). GST–S6
contains Lys218–Lys249 of Rat S6 in pGEX-3X (Pharmacia).
GST–Bad was generated by placing full-length murine Bad (from
pEBG-Bad, NEB) into pGEX-4T-1 (Pharmacia). Point mutants of Bad
(S112A, S136A and S112A,S136A) were generated using the quick-
change approach (Stratagene). Generation of an activated allele of
Rsk1 was done by cloning either the avian [10] or human Rsk1 cDNA
downstream of a DNA linker encoding six amino acids (MGSSKS) of
the Src myristoylation signal in pCMV6 (a gift of P. Tsichlis). Plasmids
pCMV6-HA-Akt and pCMV6-Myr-Akt-HA were gifts of P. Tsichlis.
HA–Rsk1 and HA–Rsk1∆∆ (K112R/K464R) were generated by placing
avian Rsk1 wild-type and mutant cDNAs into pKH3. Plasmid pRK7-Mek-
DD was a gift from R. Erikson. pCMV-GFP-PH encodes the pleckstrin
homology domain of spectrin fused to GFP (gift of R.F. Kalejta, T. Shenk
and A.J. Beavis). For cotransfection experiments, Rsk1 constructs were
cloned into pMT2, which is driven by an SV40 promoter and allowed for
efficient production of the cotransfected protein(s).
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